Like most large pharmaceutical companies, Merck invested heavily in gene expression profiling before paying much notice to proteomics. In fact, Merck’s proteomics group may have an even bigger chip on its shoulder: With the company’s acquisition of Rosetta Inpharmatics in May 2001, “there’s definitely a bias toward gene expression,” said Patrick Griffin, senior director of proteomics for Merck in Rahway, NJ.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.